ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Baltimore, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pancreatic Cancer
Colorectal Cancer
Non-Small-Cell Lung Carcinoma
Stomach Cancer
Prostatic Cancer
Neoplasm Metastasis
Esophageal Cancer

Adenocarcinoma trials near Baltimore, MD, USA:

BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (EXPEL PANC)

to determine the 18 week progression-free survival rate of the combination of BXCL701 and pembrolizumab in patients with pancreatic ductal adenocarcinoma...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Pembrolizumab
Drug: BXCL701

Phase 2

Georgetown University
Georgetown University

Washington D.C., District of Columbia, United States and 2 other locations

The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combinatio...

Enrolling
Pancreatic Adenocarcinoma Metastatic
PDAC - Pancreatic Ductal Adenocarcinoma
Drug: daraxonrasib
Drug: nab-paclitaxel

Phase 3

Revolution Medicines
Revolution Medicines

Baltimore, Maryland, United States and 12 other locations

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared...

Enrolling
Pancreatic Adenocarcinoma Metastatic
PDAC - Pancreatic Ductal Adenocarcinoma
Drug: Gemcitabine (GEM)
Drug: Nab-paclitaxel

Phase 3

Revolution Medicines
Revolution Medicines

Baltimore, Maryland, United States and 3 other locations

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

Enrolling
Resected Pancreatic Adenocarcinoma
PDAC - Pancreatic Ductal Adenocarcinoma
Drug: daraxonrasib

Phase 3

Revolution Medicines
Revolution Medicines

Baltimore, Maryland, United States and 42 other locations

(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...

Active, not recruiting
Gastroesophageal Cancer
Drug: Supportive care measures
Biological: Sacituzumab tirumotecan

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Fairfax, Virginia, United States and 168 other locations

(CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Enrolling
Gastroesophageal Junction Adenocarcinoma
Esophageal Cancer
Drug: Sonesitatug vedotin
Drug: Nivolumab

Phase 3

AstraZeneca
AstraZeneca

Washington D.C., District of Columbia, United States and 284 other locations

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

Enrolling
Pancreatic Adenocarcinoma Metastatic
PDAC - Pancreatic Ductal Adenocarcinoma
Drug: mGnP
Drug: GnP

Phase 3

Immuneering Corporation

Columbia, Maryland, United States and 22 other locations

The purpose of this study is to evaluate the safety and clinical activity of paclitaxel plus olaparib and pembrolizumab in patients with previously t...

Active, not recruiting
Advanced Gastric Adenocarcinoma
Drug: Paclitaxel
Drug: Pembrolizumab

Phase 2

Johns Hopkins Medicine
Johns Hopkins Medicine

Baltimore, Maryland, United States

This study has stopped recruitment.Adults with advanced pancreatic cancer participate in this study. The study tests a type of immunotherapy. It is a...

Active, not recruiting
Pancreatic Ductal Adenocarcinoma
Drug: ATP150
Drug: ATP152

Phase 1

Boehringer Ingelheim
Boehringer Ingelheim

Fairfax, Virginia, United States and 20 other locations

drug being developed for the treatment of pancreatic ductal adenocarcinoma (PDAC). This study will be divided into two phases, with the firs...

Enrolling
Metastatic Pancreatic Ductal Adenocarcinoma
PDAC
Drug: Irinotecan
Drug: Telisotuzumab adizutecan

Phase 2, Phase 3

AbbVie
AbbVie

Fairfax, Virginia, United States and 17 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems